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Vitamin E owes its biological effects to its antioxidant activity. Kinetic and mechanistic studies on phenolic 
antioxidants in vitro have led us to design and synthesize all-rac-2.4,6,7-tetramethyl-2-(4’.8’,12’-trimethyltri- 
decyl)-5-hydroxy-3,4_dihydrobenzofuran, 3. In the rat curative myopathy bioassay the acetate of this com- 
pound has 1.5-I .9 times the bioactivity of all-rat-a-tocopherol acetate. This represents the first time that 
a rationally designed synthetic ‘vitamin’ has been found to have more activity in vivo than the corresponding 
natural vitamin. 
Vitamin E potenq Benzojiiran analog 
1. INTRODUCTION 
Vitamin E, a mixture of four phenols (ArOH) 
called tocopherols, is believed to owe its biological 
effects to its antioxidant activity [l] which allows 
it to inhibit peroxidation in vivo by trapping chain 
carrying peroxyls (ROO ’ ) [2,3]. 
ROO’ + ArOH% ROOH + ArO- (1) 
a-Tocopherol (a-T) is biologically the most active 
of the four tocopherols [l]. It is also the most ac- 
tive at trapping peroxyls in vitro [4]. Indeed, we 
found that the rate constant for ROO * trapping, 
kl, was higher for LY-T (kYwT=3.2x lo6 M-’ ‘s-l) 
and related compounds, e.g. 1 (k! =3.8 x lo6 
M-’ *s-‘), than for any other phenols then known 
[4]. This was explained in stereoelectronic terms 
with reference to the dihedral angle, 8 (- 17” for 1) 
[4] between the p-type lone pair orbital on 01 and 
a perpendicular to the aromatic plane, an angle 
which is equal to the dihedral angle between the 
O&Z bond and the aromatic plane [4]. 
Since antioxidant activity (i.e. kl) should in- 
Pyruvate kinase Myopathy bioassa!, 
o-T 1 
crease as B decreases we predicted that appropriate 
dihydrobenzofurans would be even better antiox- 
idants than cr-T and 1. Such proved to be the case 
for 2 (k: = 5.4 x lo6 M-’ *s-l) [5] and the question 
was raised as to whether the CY-T analogue, i.e. 3, 
would have greater activity than cy-T in vitro and 
in vivo [5]. We have now synthesized all-rat-3. We 
find that its in vitro ability to trap ROO . is greater 
than that of cu-T by a factor of 1.47 (k: = 4.7 x lo6 
M-’ *s-l, hence ti/kYeT = 4.7 x 106/3.2 x 106= 
1.47). We therefore synthesized all-rat-Iacetate. 
We report herein the results of an in vivo bioassay 
of this compound comparative to that of 
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2. MATERIALS AND METHODS 
all-rat3 was synthesized by a Wittig reaction 
between 2-formyl-2,4,6,7-tetramethyl-5benzylox- 
ydihydrobenzofuran and 3,7,11 -trimethyldodecyl 
bromide followed by hydrogenation. The identity 
of the compound (a colourless, oily liquid) was 
confirmed by elemental analysis (C and H), by ‘H 
and 13C NMR, and by GC-MS of its trimethylsilyl 
ether. It was converted to the acetate which was 
then further purified by chromatography on silica 
gel. (The synthesis of this acetate by a different 
route was reported in 1948 but no supporting 
evidence (not even analysis for C and H) for its 
identity was provided [6]. Possibly the material did 
not have the ascribed structure since it was said to 
possess only a weak vitamin E activity [6]. 
The test chosen to measure relative vitamin E ac- 
tivities was the rat curative myopathy bioassay 
which was conducted essentially as described by 
Machlin et al. [7]. Male, weanling (21-22 days 
old), Sprague-Dawley rats from the NRCC specific 
pathogen-free facility were housed in individual 
stainless-steel wire mesh cages at 28 f 1°C 
(bioassays I and II) or 24? 1°C (bioassay III), 
given tap water to drink and fed ad libitum a 
modified, vitamin E-free AIN 76A diet [8]. The 
higher levels of tocopherol-stripped fat used in the 
diets for bioassays II and III (see table 1) were ac- 
commodated by an appropriate reduction in diet 
sucrose. The diet employed in III was made 
selenium-deficient by substitution of the 3.5% 
AIN 76 salt mix with 4% of selenium-free 4164 salt 
mix [8]. When the rats’ plasma pyruvate kinase 
(PPK) activities were ,) IO-times the normal values 
of 0.2 kO.02 units/ml (12-14 weeks in bioassays I
and II, 6 weeks in III), they were given one of three 
doses of the test compound daily for 4 days. In 
bioassay I test compounds were incorporated into 
an aqueous suspension of dimyristoyl lecithin 
liposomes (2 ml/kg body wt) and given by gastric 
intubation; in II and III they were dissolved in 
tocopherol-stripped corn oil and administered per 
OS (200 ,&body wt) using a positive displacement 
pipette. Blood (OS-l.0 ml) for PPK analysis was 
obtained 23-24 h after the last dose by cardiac 
puncture under halothane anaesthesia (5% in 
02, -2 min). It was mixed with NazEDTA (1 
mg/ml), chilled in ice and centrifuged at 12 000 x g 
for 1 min to sediment cells. The plasma was stored 
in ice and PPK was measured within 2 h essentially 
as described by Gutmann and Bernt [9]. The 
animals were killed after completion of these tests 
and lipid extracts from plasma and muscle tissue 
were analyzed. There was no statistically signifi- 
cant differences in the levels of a-T and 3 in either 
the plasma or the muscle of the animals in a par- 
ticular bioassay group 
In each bioassay the regression of PPK vs In 
(dose) of the test compounds was computed by the 
method of least squares. Parallelism of the dose- 
response curves of each of the compounds in a 
given bioassay was confirmed by analysis of 
variance and the ratio of potencies of any two 
compounds was determined from the horizontal 
displacement between the corresponding least 
squares lines. 
3. RESULTS AND DISCUSSION 
The results are shown in fig.1 and table 1. 
Bioassay I, which was a preliminary assay with 
four animals per point, was also used to compare 
the bioactivity of (natural) 2R,4’R,8’R-a-T- 
acetate with that of (synthetic) all-race-T-acetate. 
The biopotency of the natural isomer was found to 
be 1.29-times that of the all-rat material, which 
value lies within the range (1.16-l .62) reported in 
earlier replicate myopathy bioassays [7]. Very 
recently, it was reported that the rat myopathy test 
gives results for this pair of compounds (range 
1.43-l .52) which are very similar to those obtained 
from the classical gestation-resorption assay con- 
ducted simultaneously on the same animals (range 
1.28-l .41) [lo]. The validity of the myopathy 
assay is further attested to by the fact that 
myopathy is observed in a variety of vitamin-E 
deficient animals, including man [lo]. 
The differences in the slopes of the dose- 
response curves obtained in the different bioassays 
correspond to the differences in type and amount 
of fat in the various diets [7]. The virtual absence 
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Fig. 1. Plasma pyruvate kinase (PPK) levels of vitamin E-deficient rats vs administered ose of test compound: ( q ) afl- 
rat-a-T-acetate, (A) all-rat-3-acetate, (0) RRR-cu-T-acetate. Note that the vertical (PPK) scale in bioassay III differs 
from that in bioassays I and II. Bioassay I, 4 rats/point, initial PK level (*SE for 36 rats) 6.00*0.57 units/ml; II, 
13 rats/point, no initial PK level but one week before test PK level for 6 rats was 3.04* 0.47 units/ml; III, number 
of rats/point in parentheses, initial PK level (64 rats) 15.461irO.37 units/ml. Range of doses: I, 0.3, 1.0 and 3.0 mg/kg 
body wt per day; II and III, 0.5, 1.0 and 2.0 mg/kg body wt per day. Rats on a standard vitamin E-containing diet 
have PPK levels of -0.2. 
Table 1 
Potency ratio of all-rat-3-acetate relative to 
all-rat-a-T-acetate 
Bioassay Source of Potency Confidence Parallel 




5% corn oil 1.86 0.78-4.45 - 1.39 
10% lard 1.93 1.10-3.38 - 0.90 
10% corn oil 1.49 1.04-2.12 -6.10 
Average 1.76d 
a Slope of least-squares line fitted to each set of points. 
PPK units/ml/in (mg/kg body wt/day) 
b For 2R,4’R,8’R-c~-T-acetate/all-rac-c~-T-acetate: po- 
tency ratio = 1.29; 95% confidence limits = 0.55-3.01 
(‘ Selenium-deficient diet 
d Error f 0.18 is average of residuals 
(bioassay III) produced a very marked acceleration 
in the rate of appearance of the myopathic condi- 
tion and yielded the steepest dose-response curves 
ever reported. In each of the three bioassays the 
all-rat-3-acetate was found to be more effective in 
reducing PPK than all-rat-a-T acetate: mean 
potency ratio = 1.76, range 1.49-1.93. This in 
vivo potency ratio is rather similar to the ratio of 
1.47 found for the in vitro antioxidant activities of 
the free phenols as determined from their kr 
values. This similarity (combined with the fact that 
in related sets of experiments the levels of CY-T and 
3 in plasma and muscle did not differ significantly) 
we take to provide strong additional support for 
the traditional view that vitamin E owes its 
biological effects to its in vivo antioxidant effects. 
The measured biopotency of all-rat-3-acetate 
implies that this compound actually has slightly 
more vitamin E activity than (natural) RRR-(Y-T- 
acetate. To our knowledge, this represents the first 
time that in vitro chemical kinetic studies and the 
methods of physical organic chemistry have been 
used in vitamin research to design a compound 
which, in one test at least, ‘improves’ upon nature. 
We have recently synthesized 2R,4’R,g’R-3- 
acetate and 2S,4’R,8 ‘R3-acetate and are current- 
ly testing their biopotencies. 
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